ACE and heart failure: If cardiac systolic dysfunction develops, the offending chemotherapeutic agent(s) should be discontinued until the patient has been stabilized and started on appropriate heart failure–based therapy according to guidelines published by the American College of Cardiology, American Heart Association, and Heart Failure Society of America [173]. An ACE inhibitor or ARB, in combination with a beta-blocker, is recommended unless contraindicated.